<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02809820</url>
  </required_header>
  <id_info>
    <org_study_id>CE-9/14</org_study_id>
    <nct_id>NCT02809820</nct_id>
  </id_info>
  <brief_title>Effects of Beta-blockade on Platelet Aggregation in Acute Coronary Syndrome</brief_title>
  <acronym>PLATE-BLOCK</acronym>
  <official_title>Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators will test the hypothesis that nonselective beta-blockers would have a more
      pronounced effect on platelet aggregation than selective beta-blockers in patients with acute
      coronary syndrome treated with dual anti platelet therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with acute coronary syndrome (ACS) beta-blockers are recommended for secondary
      prevention. It is known that catecholamine levels can potentiate platelet reactivity and
      beta-blocking agents may also affect platelet aggregation. This effect is mainly mediated by
      adrenergic receptors on platelets. This suggests that nonselective beta-blockers would have a
      more pronounced effect on platelet aggregation than selective beta-blockers. However, little
      is known about the effect of beta-blockers on platelet aggregation in patients with
      cardiovascular disease and, to date, nothing is known in the setting of ACS.

      The aim of the present study is to evaluate the effect of selective and nonselective
      beta-blockers on platelet aggregation in ACS patients treated with dual anti platelet
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet aggregation</measure>
    <time_frame>30 days</time_frame>
    <description>Platelet aggregation induced by epinephrine is measured by Light Transmission Aggregometry (LTA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-days platelet aggregation</measure>
    <time_frame>30 days</time_frame>
    <description>Platelet aggregation induced by Adenosine Diphosphate (ADP) is measured by Light Transmission Aggregometry (LTA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-days clinical events</measure>
    <time_frame>30 days</time_frame>
    <description>Major adverse cardiac events (MACE) and bleedings will be evaluated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume carvedilol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who have documented ACS, who are on dual antiplatelet therapy and are randomized to assume metoprolol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Patients randomized to this group will receive carvedilol at the highest dose tolerated</description>
    <arm_group_label>Carvedilol</arm_group_label>
    <other_name>Selective beta-blocker</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol</intervention_name>
    <description>Patients randomized to this group will receive metoprolol at the highest dose tolerated</description>
    <arm_group_label>Metoprolol</arm_group_label>
    <other_name>Non Selective beta-blocker</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute Coronary Syndrome

          -  Current dual anti platelet treatment with acetylsalicylic acid and Ticagrelor

        Exclusion Criteria:

          -  ongoing prasugrel, ticlopidine or clopidogrel therapy

          -  Creatinine Clearance &lt; 30 ml/min/1.73mm2

          -  Moderate to severe anemia Hemoglobin &lt; 10 mg/dl

          -  Platelet count &gt;600000/mm3 or &lt;150000/mm3 or hematocrit &gt;50% or &lt;25%

          -  concomitant neoplastic or immune-mediated pathologies

          -  severe pulmonary pathologies

          -  contraindication to beta blocker therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Esposito, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giovanni Esposito, MD PhD</last_name>
    <phone>0817463075</phone>
    <phone_ext>0039</phone_ext>
    <email>espogiov@unina.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Federica Ilardi, MD</last_name>
    <phone>0817462240</phone>
    <phone_ext>0039</phone_ext>
    <email>fedeilardi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federico II University of Naples</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Esposito, MD PhD</last_name>
      <phone>0817463075</phone>
      <phone_ext>0039</phone_ext>
      <email>espogiov@unina.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Esposito, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Bonten TN, Plaizier CE, Snoep JJ, Stijnen T, Dekkers OM, van der Bom JG. Effect of β-blockers on platelet aggregation: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014 Nov;78(5):940-9. doi: 10.1111/bcp.12404. Review.</citation>
    <PMID>24730697</PMID>
  </reference>
  <reference>
    <citation>Ignjatovic V, Pavlovic S, Miloradovic V, Andjelkovic N, Davidovic G, Djurdjevic P, Stolic R, Iric-Cupic V, Simic I, Ignjatovic VD, Petrovic N, Smiljanic Z, Zdravkovic V, Simovic S, Jovanovic D, Nesic J. Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy. J Cardiovasc Pharmacol Ther. 2016 Jan;21(1):44-52. doi: 10.1177/1074248415581175. Epub 2015 Apr 13.</citation>
    <PMID>25868659</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>September 10, 2016</last_update_submitted>
  <last_update_submitted_qc>September 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Giovanni Esposito</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>ACS</keyword>
  <keyword>Beta Blockers</keyword>
  <keyword>platelet aggregation</keyword>
  <keyword>light transmission aggregometry</keyword>
  <keyword>Beta-Adrenergic Blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

